Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes - Wharton, Sean; le Roux, Carel W.; Bozkurt, Biykem; Platz, Elke; Bleckert, Gabriele; Ajaz Hussain, Samina; Brückmann, Martina; Startseva, Elena; Kloer, Isabel M.; Kaplan, Lee M. (Diabetes, obesity and metabolism, 2025)
Erstmals veröffentlicht: 11. November 2025